A Phase 3 interventional study of Radiotherapy 70 Gy and Radiotherapy 76 Gy in Prostate Cancer, sponsored by Abdenour Nabid. Active, not recruiting at 1 site in Canada. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-01-27.
Sponsored by Abdenour Nabid · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing bicalutamide in Prostatic Neoplasms — 5 open to participants now, 9 under way, 3 of them phase 3. bicalutamide · Prostatic Neoplasms.
Among the 55 studies testing bicalutamide in Prostatic Neoplasms, this one is the 11th largest by enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2000, is one of 21 in phase 3, and was the 12th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →5 of the 55 studies testing bicalutamide in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+ · Men only
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
Baptist Health South Florida · Sites in United States
Ages 18+ · Men only
Martin T. King, MD, PhD · Sites in United States
Ages 18+ · Men only
Marco Lorenzo Bonu · Sites in Italy
Ages 18–80 · Men only
By country, each count listing its studies:
bicalutamide: first FDA approval 1995 (CASODEX). What it is approved for, and how studies give it, is on its page →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years to 80 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 21 · Phase 3 22 · Phase 4 5
First in 1994; this study’s year is marked. 3 started in 2000.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 600 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 53 across the 54 interventional studies. Of the 42 that completed or were terminated, 10 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 55 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Abdenour Nabid as lead sponsor.
Abdenour Nabid has 1 study filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies testing bicalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00223145Phase 3Abdenour NabidStudy on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone | 2026-12-31 |
| NCT07393867Martin T. King, MD, PhDAndrogen-responsive POSLUMA-guided Intra-prostatic Boost | 2026-12-15 |
| NCT07783282Astellas Pharma Global Development, Inc.A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer | 2027-04-30 |
| NCT04025372Brigham and Women's HospitalINTREPId (INTermediate Risk Erection PreservatIon Trial) | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 55 studies testing bicalutamide in Prostatic Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The hypothesis of the proposed study would be that, due to the six months of total androgen blockade, which would include neoadjuvant hormonal therapy for four months and concomitant hormonal therapy for two months with irradiation, the investigators could reduce local failure rates for these two dosage levels, namely 70 Gy and 76 Gy. Since increasing the dose to the prostate also seems to reduce local relapse rates, the results of the two hormonal therapy groups would be compared with the results of prostate irradiation at doses of 76 Gy. This study would verify the possibility of compensating a six Gy dosage increase of radiation therapy with six months of hormonal therapy between the 70 Gy and 76 Gy groups who received hormonal therapy, and also match these results with a dose escalation to the prostate of 76 Gy. In the future, this could result in more therapeutic choices, such as reducing the doses of radiation therapy and, consequently, its related complications, if hormonal therapy proves to be beneficial; or rather, to continue in the direction of dose escalation for this intermediate-risk patient group, everything being correlated to the side effects of hormonal therapy and irradiation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Androgen blockade for 6 months + Radiotherapy 70 Gy
Radiation: Radiotherapy 70 Gy · Drug: Androgen blockade
Androgen blockade for 6 months + Radiotherapy 76 Gy
Radiation: Radiotherapy 76 Gy · Drug: Androgen blockade
Radiotherapy alone with 76 Gy
Radiation: Radiotherapy 76 Gy
Radiotherapy to the prostate
Radiotherapy to the prostate
Duration : 6 months
Also known as: Bicalutamide 50 mg, Goserelin 10.8 mg
Interval before biochemical failure
Time frame: 10 years
Toxicity of irradiation
Time frame: 10 years
Survival
Time frame: 10 years
The record gives a start of Dec 2000, a primary completion of Dec 2026 and a completion of Dec 2027. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bicalutamide